1,1,1-TRIFLUORO-2-BUTANONE Cas:381-88-4

We are 1,1,1-TRIFLUORO-2-BUTANONE CAS:381-88-4 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests


1,1,1-TRIFLUORO-2-BUTANONE

Synonyms:
2-Butanone, 1,1,1-trifluoro-
1,1,1-Trifluoro-2-butanone
1,1,1-Trifluorobutan-2-one
 
Molecular Formula: C4H5F3O
Molecular weight:126.07700

Appearance and properties: transparent colorless liquid
Density: 0.929 g/mL at 25 °C(lit.)
Boiling point: 50-51 °C(lit.)
Flash point: 1 °F
Refractive index: n20/D 1.322(lit.)

 
Our company is committed to establishing a complete fluorochemical products and technology platform to provide customers with convenient one-stop services. Our products are widely used in the manufacture of new materials, pharmaceutical research and development and the development of new pesticides. The fluorine product categories include fluorine-containing material raw materials, fluorinated reagents, fluorine-containing building blocks, fluorine-containing reagents and fluorine-containing gases for synthesis. Shanghai Fluorine Technology will strive to build a complete industrial chain from fluorine-containing raw material procurement, fluorination technology research and development, fluorine-containing product production, fluorine-containing product storage, fluorine-containing product quality control and fluorine-containing product application.
 



Market News: The QbD studies were designed concisely to minimize the use of the API and evaluate the critical product parameters that could affect the product quality attributes of the drug product, per FDA’s QbD guidance.Diphosphoric acid,mono[(2E,6E)-8-[[5-[(dimethylamino)sulfonyl]-1-naphthalenyl]amino]-3,7-dimethyl-2,6-octadienyl] ester, triammonium salt manufacturer.And, while 89 percent of seniors nationwide are now protected by COVID-19 vaccinations, less than 70 percent of the seniors living in underserved communities have been vaccinated to prevent COVID-19 infections, hospitalizations and deaths. We must stay focused on helping the most at risk.
The ChenMed primary care practices at which 100 percent of doctors and staff have received COVID-19 vaccinations include: 100 percent of Chen Senior Medical Centers in Miami; 100 percent of Dedicated Senior Medical Centers in Cincinnati, Houston, Jacksonville, Lakeland, Philadelphia, St. Louis, and Tampa Bay (Bradenton, Clearwater, Largo, Tampa, St. Petersburg);
100 percent of JenCare Senior Medical Centers in Louisville, New Orleans, and Richmond. “We’re making great progress on getting all patient-facing staff vaccinated, and our company-wide goal remains 100 percent,” explains Dr. Lane.
ChenMed has long captured monthly patient feedback using third-party vendors to capture the accurate patient experience data needed to help its primary care physicians keep nurturing outstanding relationships with members.
For the month ending June 30, 2021, the Medallia Experience Cloud survey data shows a robust ChenMed Net Promoter Score (NPS) of 82.9 — substantively higher than many best-in-industry 2021 NPS benchmarks reported by NICE Satmetrix (after collecting more than 65,000 email surveys) for iconic customer brands including Apple (60); Ritz Carlton Hotel (66); USAA (70); Alaska Airlines (71); and Costco Wholesale Corporation (80).
Medalia also surveyed 1,057 ChenMed patients in June, finding:
84 percent said it is very important for their medical care team to be COVID-19 vaccinated.
79 percent (average age 72 years) of seniors reported being more comfortable visiting a medical center when all staff is fully vaccinated.
Noting how NPS can vary by industry, region, or customer characteristics including age, income level, or time with your company, Dr. Syed reports, “Our doctors stay focused on earning trust every day by delivering truly personalized primary care. We give our patients our cell phone numbers. We encourage walk-in appointments. We really practice medicine differently, and the results are outstanding. 6-[1-Morpholin-4-yl-meth-(E)-ylidene]-6,7,8,9-tetrahydro-benzocyclohepten-5-one supplier ICER’s researchers used a two-year treatment horizon in their model but noted that it’s unclear how long patients are supposed to remain on these treatments. The model may not fully capture the challenges the disease presents to patients, ICER acknowledged. 5-[[[[3,5-bis(benzyloxycarbonyl)phenyl]amino]carbonyl]-[2-(2,3,4,5-tetrahydro-1H-3-benzazepino)carbonyl]]-6-[[(1-adamantanemethyl)amino]carbonyl]benzimidasole producer

Related Products
Product Name
beta-D-Ribofuranose 1,2,3,5-tetraacetate View Details
5-Iodo-1-pentanol acetate View Details
2-Acetylthiazole Cas:24295-03-2 View Details
ammonium sulfamate Cas:7773-06-0 manufacturer Cerium Fluoride Cas:7758-88-5 manufacturer (R)-(+)-Propylene carbonate manufacturer 2-Chlorobenzoytifluoride Cas:88-16-4 manufacturer Iodoform Cas:75-47-8 manufacturer